louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04431557: The Electroencephalogram Analysis in the Differences Between Inhalation Anesthetic and Propofol.
Official title: The Electroencephalogram Analysis in the Differences Between Inhalation Anesthetic and Propofol.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sevoflurane
Propofol
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2020-06-16
Enrollment: 268
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population was focus on the patients who need schedule general anesthesia with low anesthesia risk (ASA I-II).

Brief summary: The investigators will record 120 patients who received general anesthesia, their EEG data recorded from Bispectral Index (BIS) machine for emperical mode decomposition (EMD) analysis, the investigators decomposed EEG signal to different oscillations and tried to observe the differences between hypnotic medications through EEG analysis.

Detailed description: The electroencephalography (EEG) is a noninvasive medical technique for monitoring and recording the electrical activity of brain. The Hilbert-Huang transform (HHT) was proposed to decompose EEG signal into intrinsic mode functions (IMF) which can obtain instantaneous frequency data and work well for data that is nonstationary and nonlinear.

The relationship between frontal EEG patterns and hypnotics remain poorly understood. The investigators only can tell the increase in frontal EEG power and shift power to lower frequencies during general anesthesia from publications. The investigators are going to decompose EEG with HHT and find the energy shift during general anesthesia, compare with different anesthetics.

The investigators will record 120 patients who received general anesthesia, their EEG data recorded from BIS machine for EMD analysis, the investigators decomposed EEG signal to different oscillations and tried to observe the differences between hypnotic medications through EEG analysis.

Eligibility criteria: Inclusion Criteria:

* ASA I-II
* scheduled surgery who need general anesthesia

Exclusion Criteria:

* allergy to the BIS patch
* not suitable for general anesthesia

Primary outcomes:
measure: The gamma, beta, alpha and theta power of EEG
timeFrame: the total duration inclusions in operation room
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Feng-Fang Tsai, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02403557: Internet-delivered Cognitive Behaviour Therapy for Older Adults With Anxiety
Official title: Individually-tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Older Adults With Anxiety and Depression: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Depression
Lead sponsor: Linkoeping University
Sponsor class: OTHER_GOV
First posted: 2015-03-31
Enrollment: 66
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether tailored internet-administrated cognitive behaviour therapy (ICBT) is a feasible approach in the treatment of anxiety symptoms and comorbid depressive symptoms in older adults.


Eligibility criteria: Inclusion Criteria:

* Have anxiety symptoms

Exclusion Criteria:

* Suicidal ideation
* Alcohol addiction
* Other major primary psychiatric disorder
* Ongoing psychological treatment

Primary outcomes:
measure: Beck Anxiety Inventory (BAI)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
Secondary outcomes:
measure: Patient Health Questionnaire (PHQ)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
measure: The Generalized Anxiety Disorder 7-item Scale (GAD-7)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
measure: Quality of Life Inventory (QOLI)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
measure: Montgomery Åsberg Depression Rating Scale - Self Rated (MADRS-S)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
measure: Clinical Outcome in Routine Evaluation - Outcome Measure (CORE-OM)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
measure: Cognitive Failures Questionnaire (CFQ)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
measure: Wisconsin Card Sorting Test-64 (WCST-64)
timeFrame: Two weeks pre treatment, two weeks post treatment and 12 months post treatment
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00185757: Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Official title: Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Multiple Myeloma
Blood and Marrow Transplant (BMT)
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2005-09-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.


Eligibility criteria: Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following HLA matched allogeneic hematopoietic cell transplant

* eligible for DLI
* no evidence of GVHD
* stable immunosuppressive regimen
* adequate renal and liver function Exclusion Criteria:- CML patients who have not received DLI, active infections

Primary outcomes:
measure: To determine the feasibility of expanding allogeneic cytokine induced killer cells suitable for clinical application using a continuous perfusion culture system.
timeFrame: 21 to 28days before infusion
measure: To determine the infusional toxicity of ex vivo expanded allogeneic CIK cells in patients with recurrent or refractory disease following allogeneic hematopoietic cell transplantation.
timeFrame: day of infusion up to 24 hours after infusion
measure: To determine the incidence of Graft-versus-Host Disease (GVHD) following infusion of allogeneic CIK cells.
timeFrame: first 100 days after infusion
measure: To determine the maximum tolerated dose (MTD) of expanded CIK cells for infusion.
timeFrame: day plus 100 after infusion
Secondary outcomes:
measure: o determine the incidence of disease response following treatment with allogeneic CIK cells.
timeFrame: one year
measure: To assess donor-specific chimerism before and after treatment with allogeneic CIK cells.
timeFrame: 3 months
measure: To optimize the ex vivo expansion of CIK cells using a continuous perfusion culture system.
timeFrame: 21-28 days
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Robert S Negrin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06133257: Goal-Directed Fluid Therapy in Patients Undergoing Lower Limb Surgeries
Official title: Effects of Goal-Directed Fluid Therapy Guided by Inferior Vena Cava Collapsibility Index on Hemodynamics and Enhanced Recovery in Patients Undergoing Lower Limb Surgeries
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Anesthesia
ERAS
Fluid Overload
Hypovolemia; Surgical Shock
Lead sponsor: Zagazig University
Sponsor class: OTHER_GOV
First posted: 2023-11-15
Enrollment: 52
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Controlling the amount of fluids given to patients in perioperative setting can significantly influence their outcomes.

Detailed description: To overcome these problems and avoid the complications of over or underhydration, we use the Goal-directed fluid therapy(GDFT) guided by Inferior vena cava(IVC) collapsibility index approach in which dynamic parameters of volume responsiveness as a guide for fluid therapy. This will ensure that the fluids given were deficient from the circulation and improve the recovery of the patients according to enhanced recovery after surgery(ERAS) protocols.

Eligibility criteria: Inclusion Criteria:

* Patient's acceptance.
* Patients planned for elective lower limb surgery under spinal anesthesia.
* Both sexes
* Body Mass Index(BMI): \<35
* Age: 21 \~ 65 years
* American Society of Anesthesiologists(ASA) Physical Status Classification System: Class I \& II
* Duration of surgery 2\~3 hours

Exclusion Criteria:

* Advanced kidney, liver, respiratory or cardiovascular disease.
* Contraindication for spinal anesthesia.
* Patients shifted to general anesthesia for any reason.

Primary outcomes:
measure: Mean Arterial Blood Pressure
timeFrame: intraoperatively every 5 minutes
measure: Quality of Recovery-40 score(QoR-40)
timeFrame: 24 hours postoperative
measure: Heart Rate
timeFrame: intraoperatively every 5 minutes
measure: Post Anesthesia Care Unit(PACU) Stay
timeFrame: 2 hours postoperatively
Secondary outcomes:
measure: Total fluid intake during operation
timeFrame: intraoperatively
measure: Number of patients that needed Ephedrine or Atropine
timeFrame: intraoperatively
measure: Peripheral perfusion index
timeFrame: Intraoperatively
measure: Length of hospital stay
timeFrame: the patient will be followed up for 60 days from day of surgery
Other outcomes:
Locations:
Study officials:
affiliation: Anesthesia, Intensive Care and Pain Management department, Faculty of Medicine, Zagazig University
name: Mahmoud Abdelkader, MBBCh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06909357: Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients
Official title: Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients Throughout Florida
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Smoking Cessation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: Florida Biomedical Research Program - James & Esther King
First posted: 2025-04-03
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: Despite the deleterious impact of smoking upon cancer treatment outcomes, smoking prevalence remains alarmingly high among cancer patients. Thus, reducing smoking by cancer patients is a public health priority, but treatments to date have demonstrated limited efficacy. Mobile health (mHealth) interventions have the potential to improve treatment efficacy while also greatly extending reach. The goal of this infrastructure proposal is to build a resource to facilitate the creation of mHealth tools that address the tobacco treatment needs of cancer patients. This resource, which will be available to researchers throughout Florida, would fill a critical gap in mHealth capacity.


Eligibility criteria: Inclusion Criteria:

* ≥18 years of age.
* ≥100 lifetime cigarettes.
* English-speaking.
* Report smoking ≥ 1 cigarette in past 30 days.
* Working smartphone.

Exclusion Criteria:

* Failure to electronically confirm participation within 14 days of randomization via electronic link sent to participant's smartphone.
* Currently pregnant or breastfeeding.

Primary outcomes:
measure: Feasibility: Screening
timeFrame: At Baseline
measure: Usability: mHealth
timeFrame: Up to 6 Months
measure: Acceptability/Satisfaction: mHealth
timeFrame: Up to 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: University of Miami
state: Florida
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
Study officials:
affiliation: Moffitt Cancer Center
name: Damon Vidrine, DrPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Moffitt Cancer Center
name: Vani Simmons, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00267657: A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Official title: Assessment of Interactions Between IV Methamphetamine and Reserpine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Amphetamine-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2005-12-21
Enrollment: 30
Sex: ALL
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Detailed description: In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Eligibility criteria: Inclusion Criteria:

* Please contact site for more details

Exclusion Criteria:

* Please contact site for more details

Primary outcomes:
measure: Craving
measure: Cardiovascular
measure: Subjective symptoms/Mood Effects
measure: CNS norepinephrine turnover
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: U of CA, San Francisco
state: California
Study officials:
affiliation: Langley Porter Psychiatric Institute
name: Reese Jones, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04893057: COVID-19 Seroprevalence in Pregnant Women and Blood Donors
Official title: SARS-CoV-2 sERoprévalences Dans la Population Des Femmes Enceintes et Donneurs de Sang
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Respiratory Infection
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2021-05-19
Enrollment: 797
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult pregnant women and adult blood donors

Brief summary: The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.


Eligibility criteria: Inclusion Criteria:

* Pregnant women

  * Adult female
  * Admitted to hospital for live birth
  * Informed consent
  * Affiliated to the French social security health insurance scheme
* Blood donors

  * Adult male or female
  * Qualified for whole blood donation (up to 70 years old in France)
  * Informed consent
  * Affiliated to the French social security health insurance scheme

Exclusion Criteria:

* Legal incapacity or limited legal capacity
* Subject without health insurance coverage
* Exclusion period of another study or exclusion period of the French national healthy volunteer registry

Primary outcomes:
measure: Anti-SARS-CoV-2 spike protein total IgG
timeFrame: at inclusion
Secondary outcomes:
measure: Anti-SARS-CoV-2 nucleocapsid protein total IgG
timeFrame: at inclusion
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de besançon
Study officials:
affiliation: CHU Besançon
name: Maxime Desmarets, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04310657: mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients
Official title: mNGS Was Applied to the Study of Pathogen Identification, Precision Medication and Efficacy Evaluation of Infected Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: mNGS
Lead sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2020-03-17
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1) prospectively collected the patients with the proposed infection, confirmed the infection or excluded the infection through mNGS detection combined with traditional pathogen detection methods and clinical characteristics, compared the detection performance of mNGS and traditional methods, and explored the significance of mNGS microbial map characteristics for the diagnosis/exclusion of infection; 2) real-time dynamic monitoring of the pathogen and microecology of infected patients during the targeted drug use, and evaluation of the efficacy in combination with other indicators; 3) to explore the significance of the number of pathogen sequences before the clinical withdrawal of drugs to the clinical practice.


Eligibility criteria: Inclusion Criteria:

* 18 to 75 years old
* expected length of stay in ICU was \> 24 h
* suspected infected patients (PSI or CPIS, qSOFA or SIRS)

Exclusion Criteria:

* Pregnant and lactating women
* Who has not signed the informed consent
* the researchers considered that others were not suitable for the study

Primary outcomes:
measure: 28-day mortality
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06975657: Well-being Skills for Reentry
Official title: Community-engaged Research to Promote Mental Health and Successful Reentry Outcomes Following Incarceration
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Formerly Incarcerated Adults
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2025-05-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if a mindfulness skills training program has mental health benefits for people returning to the community following incarceration. The main questions it aims to answer are:

* Does mindfulness skills training improve symptoms of anxiety and depression?
* Do participants find this mindfulness program to be acceptable and feasible to participate in?

Researchers will compare outcomes for participants in the mindfulness training program to those in a waitlist control group who will receive the mindfulness program after the end of the study.

Participants will:

* Complete an initial intake visit, consisting of an interview and questionnaires
* Randomly be assigned to a mindfulness group or a waitlist control group
* Participate in weekly mindfulness classes for 6 weeks (mindfulness group only)
* Complete a set of questionnaires after the conclusion of the mindfulness classes
* Complete a set of questionnaires and an interview 3 months after the conclusion of the mindfulness classes


Eligibility criteria: Inclusion Criteria:

* Age 18 or older
* Formerly incarcerated in a local jail, state or federal prison
* Can speak and understand English
* Able to provide informed consent

Exclusion Criteria:

* Suicidal ideation with some intent to act or with a specific plan and intent
* Active psychosis
* Daily or nearly daily use (over the past 3 months) of the following substances: cocaine, amphetamines, inhalants, sedatives or sleeping pills, hallucinogens, or opioids

Primary outcomes:
measure: Psychological distress
timeFrame: Baseline, following week 6 of intervention period (approximately 8 weeks), 3-month follow-up after intervention period (approximately 20 weeks)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00036257: Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Lymphocytic Leukemia
Keywords: Chronic Lymphocytic Leukemia
Leukemia
CLL
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Cell Pathways
name: OSI Pharmaceuticals
First posted: 2002-05-09
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.


Eligibility criteria: Inclusion Criteria:

1. Relapsed or refractory chronic lymphocytic leukemia.
2. Patients must have either intermediate or high risk chronic lymphocytic leukemia according to the Rai Staging System.
3. Must have failed at least 1 prior chemotherapy regimen (at least 1 of which included fludarabine) for CLL.
4. No prior therapy within 4 weeks prior to entering the study. Patients must have fully recovered from the acute effects of prior therapy.
5. Platelet count = 75,000/mm3 , hemoglobin = 8 gm/dL.
6. Expected remaining life span \> or = three months.
7. ECOG performance status 0 - 2.
8. 18 years or of legal age.
9. Male patients or non-pregnant and non-lactating female patients, who are either using adequate birth control, are surgically sterile or post-menopausal.
10. Negative serum pregnancy test, if fertile female.
11. Willingness and ability to sign an informed consent document.

Exclusion Criteria:

1. Evidence of CNS involvement.
2. Other active malignancy or history of treatment of any malignancy (excluding non-melanoma skin cancer) within the previous three years.
3. Previous therapy with Campath.
4. Patients with low-risk chronic lymphocytic leukemia according to the Rai Staging System.
5. Concurrent immunotherapy.
6. Concurrent use of steroids.
7. Use of an investigational medication or device within 1 month of initiating study therapy.
8. Patients who have had allogeneic bone marrow transplantation.
9. Total serum bilirubin above the upper limit of normal; serum creatinine above the upper limit of normal.
10. AST or ALT \> 2.5 times the upper limit of normal.
11. Any condition or any medication which may interfere with the conduct of the study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Cancer Centers of Florida
state: Florida
city: Albany
country: United States
facility: Albany Regional Cancer Center
state: New York
city: Dallas
country: United States
facility: Mary Crowley Medical Research Center (US Oncology)
state: Texas
city: Tyler
country: United States
facility: Tyler Cancer Center
state: Texas
city: Spokane
country: United States
facility: Cancer Care Northwest
state: Washington
Study officials:
References: